Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) will present additional analyses from the Phase 2 VIBRANT trial of verekitug (UPB-101) in chronic rhinosinusitis with nasal polyps (CRSwNP) during a late-breaking poster session at AAAAI Congress 2026.
The poster will report efficacy and safety analyses adjusted for concomitant rescue therapy use. Presentation by Joseph Han, MD is scheduled for March 1, 2026, 9:45–10:45 a.m. EST in Convention Center Level 2, Hall E (Poster L60).
Positive
- None.
Negative
- None.
News Market Reaction – UPB
On the day this news was published, UPB gained 2.07%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $449M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
UPB was weak ahead of this news while close peers showed mixed moves: QURE and RAPP up, SYRE and VERV slightly down, TRML flat, suggesting stock-specific dynamics.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Phase 2 asthma data | Positive | -47.2% | Positive VALIANT top-line Phase 2 results in severe asthma with AAER reduction. |
| Sep 02 | Phase 2 CRSwNP data | Positive | +18.3% | Positive VIBRANT top-line Phase 2 results in CRSwNP meeting primary endpoint. |
| Jul 08 | COPD trial initiation | Positive | -0.7% | First patient dosed in Phase 2 VENTURE COPD trial expanding verekitug indications. |
Clinical trial updates have often seen negative or muted reactions, even on positive data, with one notable positive move on prior VIBRANT results.
Recent history shows Upstream Bio advancing verekitug across multiple indications. In July 2025, the company dosed the first COPD patient in Phase 2 VENTURE. By September 2025, positive top-line Phase 2 VIBRANT data in CRSwNP drove a 18.27% gain. In February 2026, positive Phase 2 VALIANT results in severe asthma were followed by a -47.18% move, indicating market skepticism or de-risking. Today’s AAAAI presentation adds deeper VIBRANT analyses within this broader Phase 2 dataset narrative.
Historical Comparison
Clinical-trial headlines over the past year averaged a -9.88% move, showing that even positive verekitug data have not consistently translated into sustained price strength.
Verekitug has progressed from initial Phase 2 COPD dosing to positive Phase 2 readouts in CRSwNP and severe asthma, with today’s AAAAI update providing deeper analyses of the earlier VIBRANT CRSwNP trial.
Market Pulse Summary
This announcement highlights additional efficacy analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP, focusing on outcomes adjusted for rescue therapy use. It extends the positive top-line data disclosed in 2025 with a dedicated late-breaking presentation at AAAAI 2026. Investors may watch how these refined endpoints compare with existing biologics, how they integrate with severe asthma and COPD data, and how they inform Phase 3 design and regulatory discussions.
Key Terms
chronic rhinosinusitis with nasal polyps medical
otolaryngology medical
phase 2 medical
AI-generated analysis. Not financial advice.
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session –
WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming late-breaking poster session at the American Academy of Allergy, Asthma and Immunology (AAAAI) Congress 2026 in Philadelphia on Sunday, March 1, 2026. The presentation features additional analyses of data from the VIBRANT Phase 2 trial of verekitug in the treatment of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). These new analyses assess the efficacy of verekitug with adjustment for concomitant rescue therapy use.
Presentation details
Presentation Title: Efficacy and Safety of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps: Results of the Phase 2 VIBRANT Trial
Presenting Author: Joseph Han, MD, Professor in the Department of Otolaryngology & Head and Neck Surgery and the Chief for the Division of Allergy, Old Dominion University (Eastern Virginia Medical School)
Poster Number: L60
Session: Late Breaking Poster Session II
Presentation Date and Time: Sunday, March 1, 2026, 9:45 am - 10:45 a.m. EST
Location: Convention Center, Level 2, Hall E
About Verekitug
Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds to the thymic stromal lymphopoietin (TSLP) receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only known antagonist currently in clinical development that targets and inhibits the TSLP receptor.
TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy. TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases.
Verekitug has advanced into three separate global, placebo-controlled, randomized Phase 2 clinical trials including the recently completed positive VIBRANT trial (NCT06164704) in patients with CRSwNP and VALIANT trial (NCT06196879) in patients with severe asthma. The VENTURE trial (NCT06981078) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) is ongoing. Additionally, in May 2025, Upstream Bio initiated the VALOUR trial (NCT06966479), a long-term extension study in eligible participants with severe asthma who completed the VALIANT Phase 2 clinical trial.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “predict,” “project,” “seeks,” “should,” “target,” “will” and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the global development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; and expectations regarding the differentiation, safety, efficacy, tolerability, and/or extended dosing interval of verekitug. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio’s ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio’s ability to fund its development activities and achieve development goals; Upstream Bio’s dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio’s ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio’s financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio’s competitors and industry; and other risks and uncertainties described in greater detail under the caption “Risk Factors” in Upstream Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
What will Upstream Bio (UPB) present about verekitug at AAAAI on March 1, 2026?
When and where is Upstream Bio's (UPB) VIBRANT poster presentation at AAAAI 2026?
Who is the presenting author for Upstream Bio's (UPB) VIBRANT Phase 2 poster at AAAAI 2026?
What specific analysis will Upstream Bio (UPB) show from the VIBRANT trial at AAAAI?
How can investors or clinicians find Upstream Bio's (UPB) VIBRANT poster at the conference?
